[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
February 1987

Induction Chemotherapy in Advanced Head and Neck Cancer: A Radiation Therapy Oncology Group Study

Author Affiliations

From the Department of Otolaryngology (Dr Jacobs) and the Division of Medical Oncology (Dr Al-Sarraf), Wayne State University, Harper-Grace Hospitals, Detroit; Department of Radiation Oncology, University of Colorado, Denver (Dr Kinzie); Radiation Therapy Oncology Group Headquarters, Philadelphia (Dr Pajak); Department of Radiation Therapy, Albert Einstein College of Medicine, Bronx, NY (Dr Davis); Sutter Community Hospital, Sacramento, Calif (Dr Hanks); Methodist Hospital, Peoria, Ill (Dr Weigensberg); and Department of Radiation Oncology, University of California at San Francisco (Dr Leibel).

Arch Otolaryngol Head Neck Surg. 1987;113(2):193-197. doi:10.1001/archotol.1987.01860020085018

• Cisplatin (cis-platinum, 100 mg/m2) and fluorouracil (1000 mg m2 d), for 120 hours' infusion every three weeks for three courses, produced a 93% overall response rate and a 54% complete clinical response at the single-institution level. The same combination was tested in the Radiation Therapy Oncology Group to evaluate the effectiveness and feasibility of this combination. An overall response rate of 86% was obtained, with a 38% complete clinical response. Only 27 of 42 patients completed planned surgery. Compliance with chemotherapy and radiation therapy was substantially better. No additional morbidity after surgical resection or postoperative radiation therapy was identified as secondary to the induction chemotherapy. We conclude that the combination of cisplatin and fluorouracil infusion is effective, with high complete clinical response rate in patients with advanced, previously untreated head and neck carcinoma.

(Arch Otolaryngol Head Neck Surg 1987;113:193-197)